This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Gastrointestinal Diseases  • Liver/ Biliary Tract/ Pancreatic Diseases  • Surgical Oncology  • Prognosis/ Outcomes  • Colon Cancer  • Oncology, Other  • Alert me on articles by topic

Development and Validation

Martin Schindl, MD; Stephen J. Wigmore, MD, FRCSE; Elspeth J. Currie, MSc; Friedrich Laengle, MD; O. James Garden, MD, FRCSE

Arch Surg. 2005;140:183-189.

Hypothesis  A prognostic scoring system for colorectal cancer liver metastases that is derived from unselected patients referred for hepatic resection would improve the applicability and increase the accuracy of prognostication.

Design  Retrospective analysis of prospectively documented data; validation against an unrelated cohort from another institution. The median follow-up was 16.4 months (95% confidence interval, 15.0-17.8 months) (original cohort).

Setting  Two tertiary referral centers at unrelated university hospitals.

Patients  Independent prognosticators of survival were derived from 337 patients with colorectal cancer liver metastases referred for consideration of liver resection, and prognostic scores were calculated in 269 patients (79.8%) (original cohort). Calculation of prognostic scores was also applied to 193 patients referred and treated in an unrelated institution (validation cohort).

Main Outcome Measures  Kaplan-Meier survival curve analysis (log-rank test) between different prognostic groups in the original and the validation cohorts.

Results  Independent prognosticators of survival were Dukes stage, number of metastases, and serum concentrations of carcinoembryonic antigen, alkaline phosphatase, and albumin. Significant differences were found in cumulative overall survival between patients assigned to good, moderate, and poor prognoses in the original and validation cohorts (P<.05). Liver resection improved survival in all prognostic groups. However, no patient with poor prognosis and only 19.7% (13 of 66) of patients with moderate prognosis survived 5 years, compared with 62.5% (10 of 16) of patients with good prognosis (P<.001).

Conclusions  This prognostic scoring system is derived from and can be applied to patients with colorectal cancer liver metastases at the time of referral for consideration of surgery. Patients with poor prognosis have no long-term benefit from curative liver resection and should therefore be considered for combined multimodal treatment.

Author Affiliations: Division of General Surgery, Department of Surgery, University of Vienna, Austria (Drs Schindl and Laengle); and Division of Hepatobiliary Surgery, Department of Surgery, The Royal Infirmary of Edinburgh, Scotland (Drs Wigmore and Garden and Ms Currie).

RELATED ARTICLE

This Month in Archives of Surgery
Arch Surg. 2005;140(2):115.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Simplified Staging System for Predicting the Prognosis of Patients With Resectable Liver Metastasis: Development and Validation
Minagawa et al.
Arch Surg 2007;142:269-276.
ABSTRACT | FULL TEXT  

Serum Albumin as a Significant Prognostic Factor for Patients with Gastric Carcinoma
Onate-Ocana et al.
Ann. Surg. Oncol. 2007;14:381-389.
ABSTRACT | FULL TEXT  

Guidelines for resection of colorectal cancer liver metastases
Garden et al.
Gut 2006;55:iii1-iii8.
FULL TEXT